Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.52 |
| ▸ | MMP12 | P39900 | 8/20 | 0.52 |
| ▸ | MMP13 | P45452 | 7/20 | 0.52 |
| ▸ | MMP14 | P50281 | 7/20 | 0.52 |
| ▸ | MMP8 | P22894 | 6/20 | 0.52 |
| ▸ | MMP16 | P51512 | 6/20 | 0.52 |
| ▸ | MMP9 | P14780 | 7/20 | 0.49 |
| ▸ | MMP1 | P03956 | 5/20 | 0.49 |
| ▸ | MMP3 | P08254 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 6/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 5/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479739 | 0.83 | MMP2 (0.55) | MMP2MMP12MMP13MMP14MMP8 | |
| SCHEMBL9079419 | 0.79 | AKR1B1 (0.52) | MMP2MMP12MMP13MMP14MMP8 | |
| SCHEMBL12477045 | 0.75 | PTGDR2 (0.47) | MMP2MMP12MMP13MMP14MMP8 | |
| SCHEMBL3555416 | 0.73 | L3MBTL1 (0.51) | TSHR | |
| SCHEMBL14764349 | 0.73 | MMP2 (0.48) | MMP2MMP12MMP13MMP14MMP8 | |
| SCHEMBL11073817 | 0.73 | AKR1B1 (0.60) | MMP2MMP12MMP13MMP14MMP8 | |
| SCHEMBL29639215 | 0.73 | KMT2A (0.54) | NPC1FABP4FABP5 | |
| SCHEMBL991380 | 0.73 | KMT2A (0.54) | NPC1FABP4FABP5 | |
| SCHEMBL14693750 | 0.73 | PTGS2 (0.51) | MMP2MMP12MMP13MMP14MMP8 | |
| SCHEMBL7792463 | 0.73 | NR1H4 (0.55) | MMP2MMP12MMP13MMP14MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2005-01-27 | — | — | US | disclosed |
| EP-1112252-A4 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | ADOLOR CORP (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6750216-B2 | HETEROCYCLIC AMINES SUCH AS 2-(2-(N-METHYLSULFAMOYL)-4-METHOXY -PHENYL)-N-METHYL-N-((1S)-1-PHENYL-2-((1-PYRROLIDINYL)ETHYL)) ACETAMIDE, ADMINISTERED AS ANALGESICS | ADOLOR CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-6492351-B1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-12-10 | — | — | US | disclosed |
| US-6486165-B2 | TREATING WITH AGONISTS AT KAPPA OPIOID RECEPTORS SUCH AS METHYL-4-(2-GLYCYL-4-(TRIFLUOROMETHYLPHENYL)ACETYL)-3-(R,S)-((1 -PYRROLIDINYL)-METHYL)-1-PIPERAZINECARBOXYLATE | ADOLOR CORPORATION | 2002-11-26 | — | — | US | disclosed |
| US-6476063-B2 | DEVOID OF CENTRAL NERVOUS SYSTEM EFFECTS; TOPICAL AND SYSTEMIC ADMINISTRATION; ANTIPRURITIC AGEENTS; ANALGESICS 1-ARYLMETHYLCARBONYL-2-PYRROLIDIN-1-YL-PIPERAZINES | ADOLOR CORPORATION | 2002-11-05 | — | — | US | disclosed |
| US-20020103164-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-6391910-B1 | OPIOID ANTAGONIST; ANALGESIC | ADOLOR CORPORATION | 2002-05-21 | — | — | US | disclosed |
| US-20020013296-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-01-31 | — | — | US | disclosed |
| US-6303611-B1 | FOR THERAPY OF HYPERALGESIS | ADOLOR CORPORATION | 2001-10-16 | — | — | US | disclosed |
| EP-1112252-A1 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | Adolor Corporation (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6239154-B1 | ARYLACETAMIDES, AGONISTS AT KAPPA OPIOID RECEPTORS. | ADOLOR CORPORATION | 2001-05-29 | — | — | US | disclosed |
| US-6057323-A | PIPERAZINE DERIVATIVES | ADOLOR CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-6054445-A | KAPPA OPIOID AGONIST ACTIVITY; ANALGESICS AND ANTI-PRURITIC AGENTS | ADOLOR CORPORATION (US) | 2000-04-25 | — | — | US | disclosed |
| WO-2000014065-A1 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | ADOLOR CORPORATION (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103164-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, HRH4 | MMP2 1865/4885MMP12 3663/4885MMP13 1827/4885 |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | MMP2 2534/4885MMP12 3804/4885MMP13 2573/4885 |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | MMP2 2293/4885MMP12 3552/4885MMP13 2675/4885 |
| US-20020013296-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, HRH4 | MMP2 1865/4885MMP12 3663/4885MMP13 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.